U.S. SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C. 20549

            Form 10-QSB - Quarterly or Transitional Report
            (Added by 34-30968, eff. 8/13/93, as amended)


(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES
    EXCHANGE ACT OF 1934

For the quarterly period ended November 30,2005.
                               -----------------

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
    EXCHANGE ACT OF 1934

For the transition period from _________________ to _____________


Commission file number 0-10035

                                 LESCARDEN, INC.
--------------------------------------------------------------------
 (Exact name of small business issuer as specified in its charter)

      NEW YORK                                   13-2538207
-------------------------------               -------------------
(State or other jurisdiction of              (I.R.S. Employer
 incorporation or organization)               Identification No.)

420 LEXINGTON AVENUE, NEW YORK SUITE 212            10170
----------------------------------------      -------------------
(Address of principle executive offices)          (Zip Code)

Issuer's telephone number (212) 687-1050
                          --------------

________________________________________________________________.
(Former name, former address and former fiscal year, if changed
                          since last report)


     Check whether the issuer (1) filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
past 90 days.

Yes [X]   No [ ]

State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date.

  Class                       	         Outstanding at Janurary 5, 2006
----------------------------            --------------------------------
Common Stock $.001 par value                        30,907,418

<PAGE>


                            LESCARDEN INC.
                            --------------
<TABLE>

                       CONDENSED BALANCE SHEET
                       -----------------------
<CAPTION>

                                ASSETS
                                ------
                                                                  November 30, 2005     May 31, 2005
                                                                     (UNAUDITED)          (AUDITED)
                                                                  -----------------     ------------
<S>                                                               <C>                   <C>

Current Assets:
     Cash and cash equivalents                                    $         694,540     $  1,030,019
     Accounts Receivable                                                    382,560           10,570
     Inventory                                                              114,845          102,441
     Prepaid Expense                                                           -               2,959
                                                                  -----------------     ------------


           Total Current Assets                                           1,191,945        1,145,989
                                                                  -----------------     ------------
                                                                  -----------------     ------------

Deferred Income Tax Asset, net of valuation allowance of
$1,654,000 and $1,666,000 at November 30, 2005 and
May 31, 2005 respectively                                                      -                -
                                                                  -----------------     ------------


Total Assets                                          		$         1,191,945        1,145,989

                                                                  -----------------     ------------
                                                                  -----------------     ------------


             LIABILITIES AND STOCKHOLDERS' Equity

Currents Liabilities:
Accounts payable and accrued expenses                             $         236,681     $    182,458

Deferred license fees                                                       890,875          947,625
                                                                  -----------------     ------------

     Total liabilities                                                    1,127,556        1,130,083
                                                                  -----------------     ------------

Commitments and Contingencies

Stockholders' Equity:
      Convertible Preferred Stock                                             1,840            1,840
      Common Stock                                                           30,907           30,907
      Additional Paid-In Capital                                         16,582,246       16,582,246
      Accumulated Deficit                                               (16,550,604)     (16,599,087)
                                                                  -----------------     ------------
      Stockholders' Equity                                                   64,389           15,906
                                                                  -----------------     ------------

         Total Liabilities and Stockholders' Equity                    $  1,191,945     $  1,145,989
                                                                  -----------------     ------------
                                                                  -----------------     ------------

</TABLE>

See notes to financial statements

<PAGE>
<TABLE>


                            LESCARDEN INC.
                            --------------

                  CONDENSED STATEMENTS OF OPERATIONS
                  ----------------------------------
<CAPTION>



                                                 (UNAUDITED)                  (UNAUDITED)
                                            For The Three Months         For the Six Months
                                             Ended November 30,           Ended November 30,
                                           ----------------------       ----------------------
<S>                                  <C>           <C>             <C>           <C>


                                             2005         2004            2005          2004
                                             ----         ----            ----          ----



Total Revenues                       $    444,971  $   573,304	   $   927,100	 $   950,296
                                     ------------  -----------     -----------   -----------

Costs and Expenses:
Cost of  Sales		                  207,577      264,060	       464,183	     489,113
Salaries Officer                           32,292       29,833          63,542        56,833
Salaries Office                            17,826       15,133          51,304        37,110
Professional Fees and Consulting           50,417	66,913	       109,029	      94,913
Research and Development	              -	           -	        20,397   	 -
Rent and Office Expenses	           14,805	16,794	        51,291	      39,033
Travel and Meetings	                   28,481	27,273	        54,608	      40,475
Taxes 	                                    3,217	 3,006	         7,957	       7,201
Insurance	                           27,317	10,802	        37,490	      11,043
Interest	                              -	         6,125	           -	      13,089
Other Administrative Expenses               6,900	15,919	        18,816	      28,057
                                     ------------  -----------     -----------   -----------
Total Costs and Expense                   388,832      455,958	       878,617	     816,867
                                     ------------  -----------     -----------   -----------
Net Income                            $    56,139   $  117,346	   $    48,483   $   133,429
                                     ------------  -----------     -----------   -----------
                                     ------------  -----------     -----------   -----------


Net Income Per Share
Basic and diluted                    $        .00  $       .00    $       .00   $        .00
                                     ------------  -----------     -----------   -----------
                                     ------------  -----------     -----------   -----------



Weighted Average Number of
  Common Shares Outstanding            30,907,418    29,830,495	   30,907,418	 29,830,495
  Basic and diluted                  ------------  -----------     -----------   -----------
                                     ------------  -----------     -----------   -----------

</TABLE>

See notes to financial statements
<PAGE>


                            LESCARDEN INC.
                            --------------

<TABLE>

                  CONDENSED STATEMENTS OF CASH FLOWS
                  ----------------------------------
<CAPTION>
                                                                                (UNAUDITED)
                                                                         For the Six Months Ended
                                                                                 November 30,
                                                                         --------------------------
<S>                                                               <C>                <C>
                                                                           2005              2004
                                                                           ----              ----


Cash Flows Provided by (Used in) Operations:
     Net Income 		                                     $    48,483      $    133,429
     Adjustments to reconcile net income to net
     cash provided by (used in) operating activities:
     Imputed interest on advances from stockholders         	             -	             9,089
     Changes in operating assets and liabilities
    (Increase) in accounts receivable			               (371,990)	  (550,000)
    (Increase) in inventory	                                        (12,404)	    (4,820)
     Decrease in prepaid expense	                                  2,959	               -
    (Decrease)Increase in accounts payable and
          accrued expenses             	                                 54,223	           111,191
    (Decrease) Increase  in deferred license fees	                (56,750)	   355,625
                                                                  -------------       ------------
     Net Cash Flow Provided by (Used In) Operations                    (335,479)	    54,514
                                                                  -------------       ------------
Cash Flows Provided By (Used In) Financing Activities:
         Advances from stockholders                                         -               30,000
         Repayment of advances from stockholders                            -              (50,000)
                                                                  -------------       ------------
       Cash Flows provided by (used in) Financing Activites                 -              (20,000)
                                                                  -------------       ------------

  (Decrease) Increase in cash                                          (335,479)	    34,514

Cash- Beginning of period                                             1,030,019	             5,966
                                                                  -------------       ------------

Cash - End of period                                              $     694,540	       $    40,480
                                                                  -------------       ------------
                                                                  -------------       ------------




</TABLE>

See notes to financial statements

<PAGE>

                            LESCARDEN INC.
                            --------------
                    (UNAUDITED) NOTES TO FINANCIAL STATEMENTS
                    ------------------------------------------
                            November 30, 2005
                            -----------------
Note 1 - General:
     The accompanying unaudited financial statements include all adjustments
that are, in the opinion of management, necessary for a fair statement of
the results for the interim periods. The statements have been prepared in
accordance with the requirements for Form 10-QSB and, therefore, do not
include all disclosures or financial details required by generally accepted
accounting principles. These condensed financial statements should be read
in conjunction with the financial statements and the notes thereto included
in the Company's Annual Report on Form 10-KSB for the year ended May 31, 2005.

     The results of operations for the interim periods are not necessarily
indicative of results to be expected for a full year's operations.

Note 2 - Operations and Significant Accounting Policies:
     Revenue from product sales is recognized upon shipment of the product,
when title to the property  transfers to the buyer as does the risk of loss,
and collectibility of the sales price is reasonably assured.

     The deferred license fee of $890,875 stated on the balance sheet relates
to licensee fees received from the Company's licensees and is being amortized
over the term of the license agreements.

Note 3 - Segment Reporting:
     Due to the materiality of the sales of its cosmetics product and food
supplements in addition to the company's CATRIX(R) Wound Dressing product,
the Company believes it has one business segment for financial reporting
purposes.

Note 4 - Inventory:
     Inventory at November 30, 2005 consists of the following:

  Finished Goods and deposit     $    47,871
  Raw Materials                       66,974
                                     -------
                                 $   114,845
                                     -------
                                     -------




<PAGE>



                            LESCARDEN INC.
                            --------------

     Management's Discussion and Analysis of Financial Condition
                      and Results of Operations
     -----------------------------------------------------------
                           November 30, 2005
                           -----------------

Results of Operations
---------------------

Overview
--------


     Since  its inception, the Company has primarily devoted its resources
to fund research, drug discovery and development for it's proprietary
biologic materials with a focus on wound healing, skin care, osteoarthritis
and cancer applications.  In recent years the Company has shifted emphasis
to developing,marketing and licensing opportunities for these technologies.

     The Company's revenues are led by, CATRIX(R) Wound Dressing, a topical
powder derived from bovine cartilage. The Wound Dressing is indicated
for the management of an array of chronic wounds and burns. In addition, the
Company derives revenue from a line of Catrix-based skin care products
targeting the Plastic Surgery, Dermatology and Spa markets. Sales of two
nutritional supplements, BIO-CARTILAGE(R) and a glucosamine polymer,
Poly-NAG(R) also contribute modestly to the Companys overall sales.


Critical accounting policies

    Our discussion and analysis of our financial condition are based upon
our financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States of America.
The preparation of these financial statements requires us to make estimates
and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses and related disclosure of contingent liabilities.
On an on-going forward basis, we evaluate our estimates, including those
related to inventories and deferred income taxes. We base our estimates on
our historical experience, knowledge of current conditions and our beliefs
of what could occur in the future considering available information. Actual
results may differ from these estimates under different assumptions or
reflect its more significant judgments and estimates used in the preparation
of its financial statements.


Revenue recognition

     Revenue from product sales is recognized upon shipment of the product, when
title to the property transfers to the buyer as does the risk of loss, and
collectibility of the sales price is reasonably assured.

Deferred license fees relate to licensees fees received from the companys

<PAGE>

licensees which are amortized over the term of the license agreements.


Inventory Valuation

     Inventories are valued at lower of cost,using first in first out method,
or market. We routinely evaluate the composition of our inventory and identify
slow-moving, excess, obsolete or otherwise impaired inventories. Inventories
identified as impaired are evaluated to determine if reserves are required.
Our evaluation is primarily based upon forecasted short-term demand for the
product.

Deferred Taxes

     The Company records a valuation allowance to reduce its deferred tax
assets to the amount that is more likely than not to be realized. While we
consider historical levels of income, expectations and risks associated with
estimates of future taxable income and ongoing prudent and feasible tax
planning strategies in assessing the need for the valuation allowance, in
the event that we determine that we would be able to realize deferred tax
assets in the future an adjustment to the deferred tax asset would increase
income in the period such determination was made.


Three months ended November 30, 2005 compared to November 30, 2004
------------------------------------------------------------------

     The Company's revenues decreased in the fiscal quarter ended
November 30, 2005 as compared to November 30, 2004 by $128,333, primarily due
to decreased sales of Catrix(R) Wound Dressing.

     Total costs and expenses during the three months ended November 30, 2005
were 15% or $67,126 lower.  The decrease was due to a 21% decrease in cost of
sales, or of $56,483 and decreases in professional fees and consulting of
$16,496, other administrative expenses of $9,019 and interest expense of
$6,125.  These decreases were partially offset by an increase in insurance
expense of $16,515.

Six months ended November 30, 2005 compared to November 30, 2004
-----------------------------------------------------------------

     The Company's revenues decreased in the six months ended November
30, 2005 compared to November 30, 2004 by $23,196 primarily due to decreased
sales of Catrix(R) Wound Dressing.

     Total costs and expenses during the six months ended November 30, 2005
were 10% or $61,750 higher than those of the comparative prior period. The
increase was principally due to higher salaries of $20,903, professional fees
and consulting of $14,116, research and development of $20,397, rent and
office expenses of $12,258, travel and meetings of $14,133 and insurance
expenses of $26,447.  These increases were partially offset by a decrease of
$24,930 in costs of sales, $9,241 in other administrative expenses and $13,089
in interest expense.

     The Company's cash balance decreased by $335,479 and accounts receivable
increased by $371,990 in the six months ended November 30, 2005 compared to an
increase in cash of $34,514 in the comparative prior year period. The Company
received advances from stockholders of $30,000 and repaid advances of $50,000
in the six months ended November 30, 2004 compared to none in the six months
ended November 30, 2005.

Liquidity and Capital Resources

Overview

     The Company had a profit of 48,483 for the six months ended November 30,
2005.  In addition, cash flows from operations decreased in the six months
ended November 30, 2005 mostly due to an increase in accounts receivable of
$371,990 which was collected in the subsequent period.

<page>


Present Liquidity
As of November 30,2005, the company's current assets exceeded it's accounts
payable and accured expenses by $955,264.

     On September 16, 2004 the Company announced that it had entered into a
license agreement with Valeant Pharmaceuticals International, granting Valeant
a 10 year exclusive license to market Lescarden's propriety product, CATRIX(R)
Wound Dressing through Europe.  This agreement expands the current relationship
between the two companies.  Valeant Iberica, (formerly ICN Iberica) a division
of Valeant Pharmaceutical, currently distributes Catrix in Spain, Portugal,
Greece, Cyprus and Malta.  The new license agreement expands the distribution
to include the 25 European Union member countries as well as the Balkan
countries, Russia and other member countries of the Commonwealth of Independent
States. Sales of CATRIX(R) commenced in the EU countries in November and
December 2004.

     On December 22, 2004 the Company announced that it had entered into a
license agreement with Daewoong Pharmaceutical Co. Ltd. Of Seoul, Korea
granting Daewoong a 10 year exclusive license to market Lescarden's
proprietary product CATRIX(R)Wound Dressing in South Korea. Daewoong is the
fourth-largest pharmaceutical manufacturer and distributor in Korea.
Implementation of this Agreement is contingent upon securing marketing
approval for the product by the Korean FDA.

     On December 8, 2005 the Company announced that it has signed an agreement
with Altermed Corporation, a subsidiary of Pascual Laboratories Inc., one of
the largest Filipino owned pharmaceutical companies in the Philippines. Under
the terms of the agreement, Pascual Laboratories will have exclusive rights to
the marketing and selling of the Company's patented product Polynag(R) SR(TM),
a clinically proven, slow release glucosamine for the treatment of
osteoarthritis. Implementation of this agreement in contingent upon securing
marketing approval for the product by the Philippine Bureau of Food and Drug.

     The material direct costs related to the CATRIX(R) Wound Dressing and
Polynag(R) products were incurred in periods prior to those presented. The
estimated costs necessary to support the products' development, other than to
finance significant inventory levels is not expected to be significant.

The Company has no material commitments for capital expenditures at
November 30, 2005.


Disclosure Controls And Procedures

     The Company maintains disclosure controls and procedures that are designed
to ensure that information required to be disclosed in the Company's filings
under the Securities Exchange Act of 1934 is recorded, processed, summarized
and reported within the periods specified in the rules and forms of the
Securities and Exchange Commission. Such information is accumulated and
communicated to the Company's management, including its Chief Executive
Officer and Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure. The Company's management, including the Chief
Executive Officer and the Chief Financial Officer, recognizes that any set of
controls and procedures, no matter how well designed and operated, can provide
only reasonable assurance of achieving the desired control objectives.

<page>


     The Company has carried out an evaluation, under the supervision and
with the participation of the Company's management, including the Company's
Chief Executive Officer and the Chief Financial Officer, of the effectiveness
of the design and operation of the Company's disclosure controls and
procedures. Based on such evaluation, the Company's Chief Executive Officer
and Chief Financial Officer concluded that the Company's disclosure controls
and procedures are effective as of the end of the period covered by this
quarterly report on form 10-QSB.

     There have been no significant changes in the Company's internal controls
or in other factors that could significantly affect the internal controls or in
other factors that could significantly affect the internal controls subsequent
to the date of their evaluation in connection with the preparation of this
quarterly report on Form 10-QSB.

<PAGE>


                            LESCARDEN INC.
                            --------------

                     Part II - Other Information
                     ---------------------------

Item 6.  Exhibits and Reports on Form 8-K
-----------------------------------------

          (A) Reports on Form 8-K: There were no reports on Form 8-K filed for
              the three months ended November 30, 2005.



                          INDEX TO EXHIBITS

           31 Certificification pursuant to Exachange Act rule 13a-14(a)
           /15d-14(a)

           99.2 Certification pursuant to 18 U.S.C. Section 1350 as adopted
           pursuant to section 906 of the Sarbanes-Oxley Act of 2002



<PAGE>